BRD2 and ovarian hyperstimulation syndrome: When corifollitropin alpha (Zander-Fox et al., 2018) or recombinant FSH (Bechtejew et al., 2017) are used in combination with oral clomiphene citrate, a reduction in the total daily dose of gonadotropins to complement COS and decrease the risk of ovarian hyperstimulation syndrome (OHSS).